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8 ABSTRACT: The aim of this work was to prepare size-tuned
9 nanovesicles using a modiﬁed ethanol injection method (EIM)
10 by applying factorial experimental design. Stable size-tuned
11 nanovesicles (liposomes and niosomes) with controlled sizes
12 and high EE values for hydrophobic compounds (Sudan Red
13 7B and vitamin D3) were achieved. Equations that were able to
14 predict the mean particle sizes, in the ranges of 55−156 nm for
15 liposomes and 224−362 nm for niosomes with PDI values
16 between 0.032 and 0.378, were obtained. These customized
17 soft nanoparticles could be suitable in food, cosmetic, pharmaceutical, or medical applications, such as diagnosis or therapy.
1. INTRODUCTION
18 Controlled preparation of nanoparticles has attracted great
19 interest in recent years.1 Nanovesicles are an important family of
20 organic nanoparticles, produced by bottom-up nanotechnology,
21 with relevant applications in biomedicine,2 food science,3
22 analytical chemistry,4,5 and biosensors.6 They are considered
23 soft nanoparticles because interactions among their molecular
24 components are similar to those arising from biological systems.7
25 Most of the work describing their preparation for speciﬁc uses
26 has focused on the optimization of their composition with the
27 aim of maximizing encapsulation eﬃciency, delivery, or delivery
28 control.
29 However, size is one of the most critical properties (together
30 with shape and surface chemistry) for understanding cell-uptake
31 processes and, therefore, bioavailability and targetability.7 Several
32 studies have focused on the optimization of the drug
33 encapsulation eﬃciency while considering size as just a property
34 for controlling administration parameters, such as penetration
35 kinetics in topical formulations. For example, Padamwar et al.8
36 studied the encapsulation of vitamin E in liposomes and found
37 that the amount of lipids yielded a positive correlation with size,
38 which was, in turn, negatively correlated with penetration
39 eﬃciency into the skin. Sometimes, size has been found to
40 increase with higher amounts of membrane components, such as
41 cholesterol, whereas it decreased with higher amounts of
42 surfactants (e.g., Tween 80). Simultaneously, cholesterol or
43 surfactants can aﬀect encapsulation eﬃciency (EE). Optimal
44 situations can be reached as a compromise at intermediate levels
45 of both factors. In that case, Taha9 also reported an interaction
46 between membrane-component concentration and size reduc-
47 tion by ultrasound, making factor optimization an essential task.
48 In other cases, an opposite eﬀect was observed, and higher
49 concentrations of membrane components (such as Span 60 and
50cholesterol) produced larger sizes and increased EEs. It is useful
51to deliver eﬃcient amounts of a selected drug into superﬁcial skin
52layers without systemic absorption.10 On this basis, the goal of
53our work was to set up a bulk method for producing nanovesicles
54of controlled size that could be subsequently modiﬁed for speciﬁc
55applications.
56Vesicles are colloidal particles in which a concentric bilayer
57made up of amphiphilic molecules surrounds an aqueous
58compartment. These vesicles are commonly used to encapsulate
59both hydrophilic and lipophilic compounds, for food, cosmetic,
60pharmaceutical, or medical applications, such as diagnosis or
61therapy.11 Hydrophilic compounds are entrapped into the
62aqueous compartments between bilayers, whereas lipophilic
63compounds are preferentially located inside the bilayers.12,13 The
64most common types of vesicles are liposomes and niosomes.
65Liposomes were ﬁrst described by Bangham et al. in 1965,14
66and they are basically spherical bilayer vesicles formed by the self-
67assembly of phospholipids. This self-assembly process is based
68on the interactions occurring between phospholipids and water
69molecules, where the polar head groups of phospholipids are
70exposed to the aqueous phases (inner and outer) and the
71hydrophobic hydrocarbon tails are forced to face each other in a
72bilayer.15 Because of the presence of both lipid and aqueous
73phases in liposome structures, they can be used for the
74encapsulation, delivery, and controlled release of hydrophilic,
75lipophilic, and amphiphilic compounds.15,16
76On the other hand, niosomes are vesicles formed by the self-
77assembly of nonionic surfactants in aqueous media resulting in
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78 closed bilayer structures.13,17,18 As liposomes, their formation
79 process is a consequence of unfavorable interactions between
80 surfactants and water molecules, and they can also entrap
81 hydrophilic, lipophilic, and amphiphilic compounds.19,20
82 Niosomes exhibit a number of advantages over liposomes,
83 such as higher stability, easy access to raw materials, lower
84 toxicity, high compatibility with biological systems, non-
85 immunogenicity, and versatility for surface modiﬁcation.20
86 Cholesterol is commonly used as a membrane additive for
87 nanovesicle preparation to improve vesicle stability, entrapment
88 eﬃciency, and release under storage.20 It increases vesicle size
89 and rigidity, improving encapsulation eﬃciency, but at high
90 concentrations, it can adversely aﬀect the encapsulation rate.21,22
91 Cholesterol also plays a fundamental role in niosome formation
92 when hydrophilic surfactants are used (hydrophile/lipophile
93 balance of ∼10).20
94 More than 20 diﬀerent methods have been identiﬁed for
95 nanovesicle preparation, and these methods were recently
96 reviewed.23,24 In this work, a modiﬁed ethanol injection method
97 (EIM) is used, because it oﬀers some advantages over other
98 methods, such as simplicity, absence of potentially harmful
99 chemicals, and suitability for scaleup.25
100 The conventional EIM was ﬁrst described in 1973.26 In this
101 technique, lipids/surfactants and additives are ﬁrst dissolved in
102 an organic solvent, such as diethyl ether or ethanol, and then
103 injected slowly through a syringe into an aqueous phase
104 containing the compound of interest. Then, the organic solvent
105 is removed using a vacuum rotary evaporator. When ethanol is
106 used as the organic solvent, the spontaneous formation of
107 vesicles occurs as soon as the organic solution is in contact with
108 the aqueous phase,27 but vigorous agitation is needed to obtain
109 narrow size distributions. For this purpose, a ﬁnal sonication
110 stage was applied in this study after organic-phase removal by
111 vacuum evaporation.
112However, a large number of variables are involved in this
113modiﬁed EIM, and selection of the most important of them
114(screening) is a crucial step in rationally preparing vesicles by this
115versatile method. In this work, the Z-average size and
116polydispersity index (PDI) were selected as the dependent
117variables. They are considered to be of great importance in
118nanovesicle design because most of the ﬁnal applications of these
119vesicular systems are directly related to these two parameters.
120Factorial experimental design and the analysis of variance
121(ANOVA) methodology are appropriate and eﬃcient statistical
122tools that permit the eﬀects of several factors that inﬂuence
123responses to be studied by varying the factors simultaneously in a
124limited number of experiments.
125In the recent past, design of experiments (DoE) has been
126extensively used for the study and optimization of vesicles and
127other similar organic materials. Diﬀerent designs can be applied
128to reduce the number of factors involved in the preparation
129techniques28 and, therefore, to minimize the number of
130experiments without losing valuable information. Plackett−
131Burman design is a type of fractional design involving relatively
132few runs,29 commonly used for the screening of variables.
133Another important role of DoE is in the optimization of
134nanovesicle composition for the enhancement of intended
135purposes. For instance, it has been applied to the formulation of
136liposomes (phospholipid and cholesterol ratio) for the topical
137delivery of vitamin E,8 hybrid liposomes (with both low- and
138high-transition-temperature phospholipids) to improve the
139encapsulation and delivery of silymarin,30 and niosomes for
140topical delivery applications.10,31 DoE has also been used to
141enhance the transdermal ﬂux of raloxifene hydrochloride32 and
142diclofenac diethylamine33 loaded transfersomes and of other
143polymeric nanoparticles encapsulating an anticancer drug.34
144Moreover, the interactions between vesicles and proteins, such as
145pectin, to improve drug-delivery properties has been studied by
Table 1. Plackett−Burman Fractional Factorial Design: Responses, Levels, and Factors
response code meaning
Y1 Z-average size of PC liposomes
Y2 PDI of PC liposomes
factors
formulation injection evaporation sonication
level O/A (X1) C (X2) (g/L) I (X3) (mM) QV (X4) (mL/h) TI (X5) (°C) NS (X6) (rpm) TE (X7) (°C) NR (X8) (rpm) A (X9) (%) t (X10) (min)
−1 5:50 2.5 10 50 30 350 35 30 25 15
1 20:50 6.0 150 215 60 900 60 120 42 30
batch X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 Y1 Y2
PB1 1 1 −1 −1 −1 −1 1 −1 1 1 90 0.254
PB2 1 −1 −1 1 −1 1 1 1 1 −1 93 0.129
PB3 −1 −1 −1 −1 −1 −1 1 1 −1 −1 97 0.152
PB4 1 −1 1 −1 1 0 1 −1 1 −1 72 0.205
PB5 −1 1 −1 1 −1 −1 1 −1 −1 1 258 0.413
PB6 1 1 1 1 −1 −1 −1 1 −1 −1 102 0.176
PB7 −1 −1 1 1 −1 −1 −1 −1 1 1 84 0.218
PB8 1 −1 −1 1 1 1 −1 1 −1 1 106 0.240
PB9 −1 −1 −1 −1 1 1 −1 1 1 1 71 0.229
PB10 1 −1 1 −1 −1 −1 −1 −1 −1 1 81 0.141
PB11 −1 1 1 −1 1 −1 1 1 −1 1 152 0.316
PB12 1 1 1 1 1 1 1 1 1 1 65 0.260
PB13 −1 −1 1 1 1 1 1 −1 −1 −1 87 0.189
PB14 −1 1 1 −1 −1 1 −1 1 1 −1 115 0.273
PB15 1 1 −1 −1 1 1 −1 −1 −1 −1 113 0.199
PB16 −1 1 −1 1 1 −1 −1 −1 1 −1 74 0.271
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146 DoE.35 Nanostructured lipid carriers (NLCs) loaded with
147 ﬂurbiprofen were also produced under optimal conditions
148 using full factorial design.36
149 In this work, an initial fractional factorial design with two levels
150 (Plackett−Burman) was used to screen the most important
151 factors in vesicle preparation by the EIM. Then, a 23 two-level full
152 factorial design using center-point replicates was applied to study
153 the inﬂuence of the main factors and their interactions on the Z-
154 average size and PDI. Once the appropriate operating conditions
155 were determined, vesicle stability was studied by using multiple
156 light scattering technology and by measuring the encapsulation
157 eﬃciencies (EEs) of diﬀerent compounds.
2. MATERIALS AND METHODS
158 2.1. Materials. Phosphatidylcholine (PC) (predominant
159 species C42H80NO8P, MW = 775.04 g/mol) from soybean
160 (Phospholipon 90G) was a kind gift from Lipoid (Ludwigshafen,
161 Germany). Sorbitan monostearate (Span 60, S60) (C24H46O6,
162 MW = 430.62 g/mol) and cholesterol (Cho) (C27H46O, MW =
163 386.65 g/mol) were purchased from Sigma-Aldrich (St. Louis,
164 MO). All membrane components were dissolved in absolute
165 ethanol (Sigma-Aldrich, St. Louis, MO).
166 Methanol, acetonitrile, 2-propanol, and acetic acid of high-
167 performance liquid chromatography (HPLC) grade were
168 supplied by Sigma-Aldrich (St. Louis, MO).
169 A phosphate buﬀer (PB) solution (10 mM, pH 7.4) was used
170 in all experiments as the aqueous phase. The buﬀer solution was
171 prepared in Milli-Q water by dissolving proper amounts of
172 sodium dihydrogen phosphate and sodium hydrogen phosphate,
173 supplied by Panreac (Barcelona, Spain). Sodium chloride from
174 Panreac (Barcelona, Spain) was added to increase the ionic
175 strength when required according to the experiments listed in
t1 176 Table 1. For the encapsulation experiments, Fat Red Bluish or
177 Sudan Red 7B dye (C24H21N5, MW = 379.46 g/mol) and
178 cholecalciferol or vitamin D3 (C27H44O, MW = 384.64 g/mol)
179 were purchased from Sigma-Aldrich (St. Louis, MO).
180 2.2. Factorial Design of Experiments. Factors that could
181 potentially aﬀect the size of vesicles produced by the EIM were
182 classiﬁed in four groups, according to the diﬀerent steps involved
183 in this preparation method: formulation (organic/aqueous phase
184 volume ratio, phospholipid concentration, and ionic strength),
185 injection (injection ﬂow rate, temperature, and stirring speed),
186 evaporation (temperature and rotation speed), and sonication
187 (amplitude and time of sonication).
188 To identify the relative eﬀects of variables on the response, a
189 two-level fractional factorial design was used. A Plackett−
190 Burman (P−B) resolution III design with n = 16 runs was
191 proposed for screening of the initial factors. Two levels were
192 selected for each variable.
193 Table 1 lists the factors and levels involved in the P−B
194 fractional factorial design used, where O/A is the organic/
195 aqueous phase volume ratio, C is the concentration of
196 phospholipid, I is the ionic strength, QV is the injection ﬂow
197 rate, TI is the injection temperature, NS is the stirring speed
198 during injection, TE is the evaporation temperature, NE is the
199 evaporator rotation speed, A is the sonication amplitude, and t is
200 the sonication time.
201 In a second step, a 23 full factorial design with center-point
202 repetitions (n = 5) was carried out to study the main eﬀects and
203 interactions between factors previously selected by the screening
t2 204 design (Table 2). All other factors were ﬁxed at certain values.
205 In both designs, mean diameter (Z-average size) and PDI were
206 selected as response variables. Minitab statistical software
207(version 17) was used for all data analysis. Analysis of variance
208(ANOVA) was used for this purpose.
209Once the models were obtained taking into account signiﬁcant
210factors and interactions, a set of selected size-tuned vesicles were
211prepared and characterized.
2122.3. Vesicle Preparation. For liposome preparation,
213appropriate weighed amounts of PC were dissolved in diﬀerent
214volumes of absolute ethanol (5−20 mL range). The same
215procedure was applied to niosome preparation by weighing and
216dissolving S60 and Cho in a 1:0.5 weight ratio. Then, the organic
217solution was injected, with a syringe pump (KD Scientiﬁc,
218Holliston, MA) at a ﬂow rate of 120 mL/h, into Milli-Q water
219that was kept at 60 °C and stirred at 500 rpm. Once vesicles
220formed, ethanol was removed at 40 °C under reduced pressure
221(90 kPa) in a rotary evaporator. The resulting vesicular systems
222were further sonicated for 15 min (CY-500 sonicator, Optic
223Ivymen System, Biotech SL, Barcelona, Spain), using and
224amplitude of 30−55%, a power of 500 W, and a frequency of 20
225kHz. The sonication probe was placed in a 100mL glass beaker at
226a constant depth, 1.5 cm above the container bottom.
2272.4. Vesicle Characterization. 2.4.1. Vesicle Size. The Z-
228average size and PDI of vesicles were determined by dynamic
229light scattering (DSL) using a Zetasizer Nano ZS system
230(Malvern Instruments Ltd., Malvern, U.K.). Three independent
231samples were taken from each formulation, and measurements
Table 2. Full Factorial Design (23) with Center-Point
Repetitions (n = 5): Factors, Levels, and Responses
response code meaning
Y1 Z-average size of PC liposomes
Y2 PDI of PC liposomes
Y3 Z-average size of S60:Cho niosomes
Y4 PDI of S60:Cho niosomes
factors
level O/A (X1) C (X2) (g/L) A (X3) (%)
−1 (low) 5:50 2 30
0 (medium) 12.5:50 5 42.5
1 (high) 20:50 8 55
batch X1 X2 X3 Y1 Y2 Y3 Y4
FF1 1 −1 1 65 0.299 305 0.075
FF2 1 1 −1 97 0.249 362 0.136
FF3 −1 1 −1 149 0.296 294 0.206
FF4 −1 1 1 88 0.307 262 0.291
FF5 −1 −1 1 64 0.342 242 0.120
FF6 1 1 −1 100 0.257 360 0.143
FF7 1 1 1 64 0.272 241 0.182
FF8 −1 −1 −1 90 0.196 235 0.078
FF9 0 0 0 82 0.219 301 0.195
FF10 1 −1 −1 84 0.205 253 0.032
FF11 −1 1 1 107 0.297 276 0.235
FF12 −1 1 −1 156 0.308 275 0.145
FF13 1 −1 1 65 0.378 248 0.066
FF14 1 −1 −1 97 0.246 268 0.045
FF15 −1 −1 −1 84 0.173 239 0.094
FF16 0 0 0 75 0.224 305 0.253
FF17 0 0 0 84 0.250 317 0.118
FF18 1 1 1 55 0.307 224 0.203
FF19 0 0 −1 77 0.242 308 0.241
FF20 0 0 0 84 0.251 337 0.171
FF21 −1 −1 1 69 0.343 233 0.124
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232 were performed three times at room temperature without
233 dilution.
234 2.4.2. Vesicle Morphology.Morphological analysis of vesicles
235 was carried out by negative staining transmission electron
236 microscopy (NS-TEM), using a JEOL-2000 Ex II transmission
237 electron microscope (Tokyo, Japan). A sample drop was placed
238 on a carbon-coated copper grid, and excess sample was removed
239 with ﬁlter paper. Then, a drop of 2% (w/v) phosphotungstic acid
240 (PTA) solution was applied to the carbon grid and allowed to
241 stand for 1 min. Once the excess staining agent had been
242 removed with ﬁlter paper, the sample was air-dried, and the thin
243 ﬁlm of stained and ﬁxed vesicles was observed with the
244 transmission electron microscope.
245 2.4.3. Vesicle Stability. Vesicle stability was determined by
246 measuring backscattering (BS) proﬁles in a Turbiscan Lab Expert
247 apparatus (Formulaction, L’Union, France) provided with an
248 aging station (Formulaction, L’Union, France).
249 Samples were placed in cylindrical glass test cells, and
250 backscattered light was monitored at 30 °C as a function of
251 time and cell height every 2 h for 7 days.
252 The optical reading head scans the sample in the cell,
253 providing BS data every 40 μm in percentages relative to
254 standards as a function of the sample height (in millimeters).
255 These proﬁles build up amacroscopic ﬁngerprint of the sample at
256 a given time, providing useful information about changes in the
257 size distribution or appearance of a creaming layer or a
258 clariﬁcation front with time.3,37,38
259 2.4.4. Encapsulation Eﬃciency (EE). EE also provides useful
260 information related to the stability of the vesicle membrane.
261 Hydrophilic compounds are entrapped in aqueous compart-
262 ments between bilayers, whereas lipophilic compounds are
263 preferentially located within the surfactant or lipid bilayer.39
264 Substances such as drugs, bioactive compounds, dyes, and
265 nanomaterials incorporated into vesicles can also aﬀect the
266 morphology and stability of the ﬁnal dispersion.
267 For the purpose of determining EEs, Sudan Red 7B and
268 vitamin D3 (hydrophobic compounds) were encapsulated in the
269 two diﬀerent formulations.
270 Each compound was analyzed by reverse-phase high-perform-
271 ance liquid chromatography (RP-HPLC) (HP series 1100
272 chromatograph, Hewlett-Packard, Palo Alto, CA). Before RP-
273 HPLC analysis could be performed, the nonencapsulated
274 compound had to be removed by passing the sample through a
275 Sephadex G-25 column (GE Healthcare Life Sciences,
276 Wauwatosa, WI). Then, both ﬁltered and nonﬁltered samples
277 were diluted 1:10 (v/v) with methanol to facilitate vesicle
278rupture and to extract the encapsulated compound. EE was
279calculated according to the equation
= ×EE (%) peak area of filtered sample
peak area of unfiltered sample
100
280(1)
281The RP-HPLC system was equipped with an HP G1315A UV/
282vis absorbance detector (Agilent Technologies, Palo Alto, CA).
283The column was a Zorbax Eclipse Plus C18 column with a
284particle size of 5 μm, 4.6 mm × 150 mm (Agilent Technologies,
285Palo Alto, CA). The mobile phase consisted of a mixture of (A)
286100% Milli-Q-water and (B) 100% methanol with gradient
287elution at 0.8 mL/min. The step gradient started with a mobile
288phase of 80% A, running 100%mobile phase B starting in minute
2895 for 10 min. Mobile phase B was fed for 2 min after each
290injection to prepare the column for the next sample. The
291separation was carried out at 30 °C. Diﬀerent wavelengths were
292used for the UV/vis detector, namely, 533 nm for Sudan Red 7B
293and 270 nm for vitamin D3.
3. RESULTS AND DISCUSSION
2943.1. Eﬀects of Variables on Morphological Character-
295istics. The responses (Z-average size and PDI) of each batch
296from P−B design were measured by dynamic light scattering
297(DLS). The relative importance of the main eﬀects on the Z-
298average size and PDI of PC liposomes are shown in the Pareto
299 f1chart given in Figure 1.
300Researchers must be aware of the confusion of main eﬀects
301with two-factor interactions in this type of design (resolution III),
302where the alias structure is too complex. However, we decided to
303use the initial Plackett−Burman design only for screening
304purposes and selection of the main factors from the Pareto chart,
305as is usually accepted. Eﬀects were selected by applying the
306hierarchical ordering principle, known sometimes as the sparsity-
307of-eﬀects principle, where higher-order eﬀects (three- or four-
308way interactions) are sacriﬁced to study lower-order eﬀects
309(main eﬀects ﬁrst and two-way interactions next). This principle
310suggests that priority should be given to the estimation of lower-
311order eﬀects, especially when resources (time and money) are
312scarce. This postulate is an empirical principle whose validity has
313been conﬁrmed by the analysis of many real experiments.
314According to these data, the most important variables for both
315responses are the organic/aqueous phase volume ratio, the (ﬁnal
316aqueous-phase) phospholipid concentration, and the sonication
317amplitude. These results are in good agreement with previous
318studies carried out by Kremer et al.,40 who evaluated the eﬀects of
Figure 1. Pareto chart of the standardized eﬀects of independent variables (factors) on the (A) Z-average size and (B) PDI of PC liposomes for the
Plackett−Burman fractional factorial design.
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319 some preparation variables on the size and polydispersity of
320 liposomesmade from two diﬀerent natural phosphatidylcholines.
321 Their experimental results showed that the most important
322 factor in the ﬁnal size of the liposomes was the lipid
323 concentration in the alcohol injected into the buﬀer solution.
324 This factor corresponds to the interaction of the lipid amount
325 and the ﬂow rate of organic solvent injected, two factors present
326 in the Pareto chart in Figure 1. The same explanation was
327 postulated by other authors,8,41,42 conﬁrming that the lipid
328 concentration clearly aﬀects the liposome size. This factor was
329 found to be the most relevant one for controlling morphological
330 characteristics of phosphatidylcholine liposomes. Szoka43 found
331 that stirring, ionic strength, and temperature of the aqueous
332 phase could also contribute to the ﬁnal size, but the eﬀects of
333 these factors were smaller than those observed for lipid
334 concentration, organic/aqueous phase ratio, and chemical nature
335 of the organic solvent (a parameter not included in our study).
336 Therefore, the experimental results in Figure 1 conﬁrm the
337 previously reported observations.43
338 The ethanol injection method is usually chosen because it
339 avoids the sonication step, which is needed in several other
340 methods of liposome preparation, such as the thin-ﬁlm hydration
341 method. Preliminary experiments (data not shown) indicated
342 that sonication is a crucial step for reducing the size of both
343 liposomes and niosomes. Alternatively, small vesicles can be
344 produced without sonication by using low concentrations of
345 lipids/surfactants, but with low yield. This is why we decided to
346 include this step as a factor in the present study.
347 3.2. PC Liposomes. The ﬁrst three main eﬀects from the
348 Pareto chart obtained for the P−B design were selected for the 23
349 full factorial design. The ANOVA results for Z-average size and
350 PDI values are listed in Tables S1 and S2 (Supporting
351 Information), respectively, whereas the corresponding Pareto
f2 352 chart is shown in Figure 2. Mean sizes in the range of 55−156 nm
353 with PDI values between 0.173 and 0.378 were obtained for PC
354liposomes (with standard deviations ranging from 0.304 to 4.40
355nm for size and from 0.003 to 0.053 for PDI). Similar size ranges
356were also obtained using the EIM in other previously reported
357studies.22,27,41,43,44
358The normality, variance homogeneity, and randomness
359assumptions were tested with a normal probability plot,
360frequency histogram, and residuals versus ﬁts and residuals
361versus order plots, respectively (Supporting Information, Figure
362S2).
363No clear aberrant tendencies were observed, because the
364residuals tended to form a line, no typical cornet pattern was
365observed, and no time-based pattern was detected. Only some
366outlier values were detected (Cook’s distance and DFITS values
367are given in Table S3 of the Supporting Information).
368The ANOVA results allowed for an analysis of the
369contributions of the eﬀects of the independent variables on the
370response function (mean size of PC liposomes). In this case,
371signiﬁcant two-way interactions were identiﬁed: (O/A) × C and
372 f3C × A (see Figure 3). Larger sizes are reached when the organic
373solution has a higher lipid concentration (more than 20 g/L). On
374the other hand, the C × A interaction reveals that the degree of
375size reduction upon application of a higher amplitude depends
376on the total lipid concentration present in the medium (referred
377to the ﬁnal volume of the dispersion).
378All of the main eﬀects are signiﬁcant (p < 0.05), with a positive
379eﬀect on the mean size (a higher response value with an increase
380in the factor level) for the total lipid concentration and a negative
381eﬀect (a lower response value with a decrease in factor level) for
382the organic/aqueous phase volume ratio and the sonication
383amplitude.
384These eﬀects can be explained according to a previously
385reported vesicle formation model.45−47 This model relies on the
386formation of vesicles through intermediate structures, such as
387phospholipid bilayer fragments and sheet-like micelles. These
Figure 2. Pareto chart of the standardized eﬀects of independent variables (factors) on the (A,C) Z-average size and (B,D) PDI of (A,B) PC liposomes
and (C,D) S60:Cho niosomes (1:0.5, w/w) for the 23 full factorial design.
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388 intermediates are the result of amphiphilic self-assembly because
389 of their characteristic physicochemical properties.48
390 During the injection of ethanol droplets into the aqueous
391 phase, lipid reorganization inside these dispersed droplets to
392 form bilayers is favored by the fact that lipids energetically prefer
393 a parallel molecular arrangement.45 These planar structures give
394 rise to closed vesicles when their size induces enough surface
395 tension to close the structure and minimize the bending energy.
396 The sizes of these intermediates depend directly on the
397 number of lipid molecules (concentration) and the dispersion
398 degree (solubilization) in the organic phase. It is obvious from
399 the previous assessment that higher concentrations of lipids in
400 the droplets will form higher membrane fragments, as our
401 experimental results and previous observations conﬁrm.8,40−42
402 It is also important to know how easily lipid droplets are
403 dispersed, as well as their size and homogeneity. Lipids of higher
404 solubility will then form smaller lipid droplets and, consequently,
405 shorter membrane fragments (and ultimately tiny vesicles).40
406 This explains, in a simpliﬁed way, why higher organic/aqueous
407 phase ratios yield smaller liposomes.
408 The negative eﬀect of the sonication amplitude is explained by
409 vesicle rupture, which takes place when an excess of energy is
410applied to vesicles during the sonication process as a result of the
411eﬀect of induced cavitation.49,50 The ﬁnal eﬀect of ultrasounds
412can be controlled by varying the input power, ultrasound
413frequency, sonication time, and probe depth into the container.
414As frequency increases, liposomes of smaller size are produced as
415a result of stronger acoustic cavitation events. This assumption
416was conﬁrmed by our results, in accordance with previous
417studies.49,50 It is important to point out that, to minimize the
418eﬀects of variations in the probe depth, this factor was kept
419constant at 1.5 cm above the container bottom.
420Another aspect to be taken into consideration is the eﬀect of
421sonication time. It was reported by Silva et al.49 that sonication
422time plays an important role in decreasing vesicle size, although
423they observed that this eﬀect reached a plateau at about 21 min.
424Our P−B design revealed a positive eﬀect of sonication time on
425the Z-average size (from 15 to 30 min), although it was weaker
426than the eﬀects of the other variables selected for the 23 full
427factorial design (especially sonication amplitude). A similar
428inﬂuence was observed for the PDI response, but with a stronger
429eﬀect. We preferred to select sonication amplitude instead of
430sonication time because one of the goals of controlling factors is
431to obtain a narrow size distribution.
Figure 3. Three-dimensional (3D) response surface plots for the factors O/A (organic/aqueous phase volume ratio), C (lipid or surfactant/stabilizer
concentration, g/L), and A (sonication amplitude, %) for the (A,C) Z-average size and (B,D) PDI of (A,B) PC liposomes and (C,D) S60:Cho niosomes
(1:0.5, w/w).
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432 As the design included a center point with several repetitions
433 (n = 5), the presence of curvature in the response variables could
434 be tested (Figure 3). Because curvature seemed to be signiﬁcant
435 (p < 0.05), a term involving center point (Ct Pt) was included in
436 the equations for its estimation.
437 With all of this information about the eﬀects and their
438 estimated coeﬃcients, the following equation (R2 = 96.69%) for
439 the Z-average size value of PC liposomes (Y1) was generated
= + + −
− × − × −
Y C A
C C A
62.8 2.55(O/A) 0.449 0.185
0.0185(O/A) 0.00555 9.26(Ct Pt)
1
440 (2)
441 Diﬀerent behavior was observed regarding PDI, which was
442 strongly aﬀected by the sonication amplitude as the only
443 signiﬁcant main eﬀect and its interaction with the total lipid
444 amount. The O/A × C interaction was also detected, but with a
445 lower eﬀect on the PDI response.
446 To understand the C × A interaction, it is important to take
447 into account the eﬀect of the sonication amplitude as the main
448 eﬀect. An increase in this factor leads to a less monodisperse size
449 distribution, that is, higher PDI values. However, according to
450 the interaction, this response depends highly on the total amount
451 of lipids present in the sample. At a low level of the lipid amount,
452 the reduction in size is more eﬀective (as previously mentioned),
453 but the size distribution is large. However, at a high level of the
454 lipid amount, this enlargement of the size distribution is
455 signiﬁcantly lower.
456 Curvature in the response was also tested, again revealing a
457 signiﬁcant presence (p < 0.05). For the PDI response (Y2), the
458 following equation with an R2 value of 89.35% was obtained
= − + − ×
− × −
Y A C
C A
0.160 0.00939 0.0000420(O/A)
0.0000250 0.0425(Ct Pt)
2
459 (3)
460 These equations were formulated with uncoded coeﬃcients,
461 making it easier to use them to predict selected target size and
462 PDI values.
463 3.3. S60:Cho Niosomes. To investigate whether the
464 selected factors in the P−B design for PC liposomes (a reference
465 model for vesicular systems) produced similar eﬀects with other
466 diﬀerent formulations, the same 23 full factorial design using
467 center-point replicates was performed for a typical niosome
468 formulation, in this particular case, S60:Cho niosomes (1:0.5, w/
469 w). The main variables were the organic/aqueous phase volume
470 ratio (O/A), the total concentration of surfactant and stabilizer
471 (C), and the sonication amplitude (A).
472 The ANOVA results for Z-average size and PDI values are
473 listed in Table S1 (Supporting Information), and the
474 corresponding Pareto chart and three-dimensional surface plot
475are shown in Figures 2 and 3, respectively. Mean sizes in the
476range of 224−362 nm with PDI values between 0.032 and 0.291
477were obtained for S60:Cho niosomes (with standard deviations
478ranging from 1.05 to 7.28 nm for size and from 0.009 to 0.052 for
479PDI). Similar size and PDI ranges were reported for niosomes
480prepared by the EIM using Span 60 as the membrane
481component.17
482Two-way interactions (O/A × A, C × A) and a three-way
483interaction (O/A × C × A) were detected, with sonication
484amplitude (A) as the common factor in these interactions (see
485Figure 2C). Therefore, it can be postulated that sonication
486amplitude is the key factor in the niosome size response. The
487response depends on both the O/A and C factor levels, with a
488higher interaction between the sonication amplitude and the
489total amount of membrane components. Diﬀerences in the
490magnitude of the coeﬃcient of this factor between liposomes and
491niosomes can be attributed to the initial size before sonication
492(smaller for liposomes) and vesicle stability.50
493The three main eﬀects are signiﬁcant, but in contrast to the
494case for liposomes, the organic/aqueous phase volume ratio (O/
495A) shows a positive eﬀect on niosome size. This behavior could
496be due to diﬀerent molecular features of the surfactant and
497stabilizer that result in diﬀerent interactions with the organic
498phase and, therefore, poor or insuﬃcient solubility.
499The other two variables (C, A) have eﬀects similar to those
500described above for liposomes. Therefore, the same explanation
501regarding surfactant concentration and sonication amplitude can
502be applied here to justify their eﬀects on niosome size. In this
503case, the stronger eﬀect of C is explained by the inﬂuence of
504cholesterol on the ﬁnal size of vesicles, as reported by Padamwar
505and Pokharkar.8
506Once again, curvature was detected for the Z-average size
507response. The following equation was obtained to model this
508case, with an adjusted correlation coeﬃcient (R2) of 91.27%
= − − −
+ × + ×
− × × +
Y C A
C C A
C A
236.9 4.31(O/A) 0.012 0.56
0.0461(O/A) 0.00363
0.00114(O/A) 44.00(Ct Pt)
3
509(4)
510On the other hand, a completely diﬀerent behavior was observed
511regarding the PDI response. Only the three main eﬀects (O/A,C,
512A) were found to be signiﬁcant, and no interactions were found.
513Two positive eﬀects on the niosome PDI were detected:
514surfactant/stabilizer concentration and sonication amplitude. In
515this case, the total concentration of membrane components
516seemed to have an important role in the vesicle size distribution,
517as can be seen in the correspondent Pareto chart (Figure 2). This
518observation once again can be attributed to the solubilization of
519membrane components in the organic phase. Higher concen-
Table 3. Estimated Coded Coeﬃcients for the Considered Eﬀects on the Z-Average Size and PDI of PC Liposomes and S60:Cho
Niosomes (1:0.5, w/w)
coeﬃcientsa
response constant X1 X2 X3 X1X2 X1X3 X2X3 X1X2X3 R
2
Z-Average Size
liposome (Y1) 89.68 −11.14 12.40 −17.50 −11.75 − −5.97 − 96.69
niosome (Y3) 269.82 12.72 16.87 −15.94 − −12.15 −19.92 −16.04 91.27
PDI
liposome (Y2) 0.280 − − 0.038 −0.012 − −0.029 − 89.35
niosome (Y4) 0.136 −0.026 0.057 0.026 − − − − 84.73
aX1, organic/aqueous phase volume ratio; X2, PC or S60:Cho concentration (g/L); X3, sonication amplitude (%).
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520 trations of these components require better solubilization in
521 dispersed droplets to reach small membrane fragments.
522 It is important to note that some combinations of factors
523 yielded narrow size distributions, namely, PDI ≤ 0.100, a value
524 frequently obtained by other preparation methods, such as
525 microﬂuidic hydrodynamic focusing51 also using S60:Cho as the
526 formulation.
527 A negative eﬀect was detected for the organic/aqueous phase
528 volume ratio (O/A). As the ﬁnal concentration of ethanol
529 increased during the injection process, a smaller size distribution
530 was obtained. As previously mentioned, no interaction between
531 this factor and the total concentration of membrane components
532 was observed.
533 The following equation with an R2 value of 84.73% was
534 obtained for the niosome PDI model response (Y4)
= − + +
+
Y C A0.053 0.00392(O/A) 0.000039 0.00067
0.0597(Ct Pt)
4
535 (5)
536The estimated coded coeﬃcients for the considered eﬀects on
537the Z-average sizes and PDIs of PC liposomes and S60:Cho
538 t3niosomes are listed in Table 3, as a summary of the factors’
539inﬂuence. Coded coeﬃcients were used to maintain the
540orthogonality of the designs and to allow for a direct comparison
541between coeﬃcients.
5423.4. Vesicle Characterization. Size-tuned vesicles were
543prepared under selected operating conditions by applying the
544models obtained from the experimental design (eqs 2−5) and
545the assistance of the response optimizer and response predictor
546in Minitab statistical software (version 17). These tools can be
547applied to the simultaneous optimization of several responses
548only when the same set of factors are studied separately, because
549a common experimental region is needed.
550The operating conditions were selected to prepare PC
551liposomes with a mean size of 70 nm and the minimum PDI
552value (predicted values of Y1 = 67 ± 4 and Y2 = 0.317 ± 0.013)
553and S60-Cho niosomes with a mean size of 240 nm and the
Figure 4.Optimization plot and values of individual (d) and composite (D) desirability provided by the response optimizer (Minitab, version 17) for an
example of size-tuned PC liposome (desired size = 70 nm, with a minimum PDI value).
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554 minimum PDI value (predicted values of Y3 = 239 ± 11 and Y4 =
555 0.120± 0.025). These sizes and PDI values were selected only as
556 an example. The factor output values were O/A = 5:50, C = 2 g/
557 L, and A = 55% for the liposomes and O/A = 5.9:50, C = 2 g/L,
f4f5 558 andA = 55% for the niosomes. Figures 4 and 5 show optimization
559 plots and values of individual and composite desirability for size-
560 tuned liposomes and size-tuned niosomes, respectively.
561 The experimental results showed that the models obtained
562 with the experimental design were accurate, because mean sizes
563 of 69 ± 0.5 nm (PDI = 0.245 ± 0.005) and 233 ± 3 nm (PDI =
564 0.112± 0.004) were obtained for the PC liposomes and S60:Cho
565 niosomes, respectively. The relative error was low for the
566 experimental results regarding mean size (3% for Y1 and Y3) but
567 higher for the size distributions (22% for Y2 and 7% for Y4).
568 The sizes and morphologies of the vesicles were investigated
f6 569 by TEM, using a negative contrast. Figure 6 shows black-stained
570vesicles, as a result of the interactions of the electron beam with
571PTA, which produces a selective deposit of metal ions that
572enhances morphological details. Themicrographs show spherical
573structures of approximately 80 nm for the liposomes (Figure 6C)
574and about 250 nm for the niosomes (Figure 6D). These values
575agree with the DLS measurements.
576Figure 6D shows clusters of niosomes that are all similar in
577size. Aggregation arose during the drying step prior to TEM
578measurements, because no ﬂocculation phenomena were
579monitored with the Turbiscan apparatus.
580Slight diﬀerences were noticed in the zeta potential measure-
581ments, exhibiting low values for both types of vesicles. Niosomes
582had values of about −16.8 ± 0.7 mV, whereas the liposomes had
583values of−6.9± 0.3 mV. This small value for the liposomes could
584be due to neutralization of the negative charge from the
Figure 5.Optimization plot and values of individual (d) and composite (D) desirability provided by the response optimizer (Minitab, version 17) for an
example of size-tuned S60:Cho niosome (1:0.5 w/w) (desired size = 240 nm, with a minimum PDI).
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585 phosphate groups by sodium cations present in the medium
586 (from sodium chloride in the PB solution).
587 The formulated vesicles exhibited a high stability after 1 week
588 of monitoring time. BS proﬁles obtained for the PC liposomes
589 are given in Figure 6, where a variation of 4.5% in the middle part
590 of the cell (from 10 to 30 mm) is noticed. A simultaneous slight
591 clariﬁcation process was observed in the middle and top parts of
592 the cell in the corresponding transmission proﬁle (results not
593 shown). This was promoted by some movement of the PC
594 liposomes toward the bottom of the cell, resulting in a slight
595 increase in BS (sedimentation). However, this was a reversible
596 process, caused by diﬀerences in concentration, with the sample
597 remaining stable and maintaining its initial properties (size and
598 PDI). The vesicles were again characterized after gentle agitation
599 of the cell at the end of the monitoring time with analogous
600 results.
601 For the S60:Cho niosomes (Figure 6B), the BS proﬁle
602 remained nearly constant (variations of approximately 0.5%)
603 with time, showing high stability. Some variation was also
604 observed in the transmission proﬁle all along the cell height,
605 because the sample was not translucent.
606 3.4.1. Encapsulation Eﬃciency (EE). Vesicles containing
607 Sudan Red 7B and vitamin D3 as model compounds (both
608 lipophilic) were also prepared and characterized. No diﬀerences
609 were observed regarding mean size and PDI values or TEM, zeta
610 potential, or Turbiscan measurements, meaning that the
611 entrapped compounds did not aﬀect the vesicle’s behavior.
612High EE values were obtained for both Sudan Red 7B and
613vitamin D3, as expected taking into account their hydrophobic
614character. EE values up to 90.1% and 88.0% were obtained for
615Sudan Red 7B encapsulated in PC liposomes and S60:Cho
616niosomes, respectively. Experiments carried out with vitamin D3
617led to EE values of 99.2% for PC liposomes and 73.9% for
618S60:Cho niosomes. These results are in good agreement with
619those of previous studies, where compounds with similar
620chemical properties were encapsulated.12,13,27
4. CONCLUSIONS
621In this work, an adequate approximation using DoE was applied
622to study the inﬂuence of experimental factors of the EIM on the
623mean size and size distribution of PC liposomes and S60:Cho
624niosomes (1:0.5, w/w).
625An initial screening design enabled a reduction of the number
626of variables. This was a necessary step before carrying out a full
627factorial design. Finally, response models were applied to prepare
628selected size-tuned nanovesicles, which were characterized from
629a stability point of view.
630This was achieved with a low number of experiments (58
631runs). This methodology enabled two diﬀerent formulations
632(liposomes and niosomes, the most common types of nano-
633vesicles) to be studied in a comparative way. Stable liposomes
634and niosomes of the targeted sizes were successfully prepared
635with the model equations obtained, with encapsulation
636eﬃciencies higher than 73.9% in all cases for selected
637hydrophobic compounds.
Figure 6. (A,B) BS proﬁles and (C,D) TEM micrographs of empty vesicles designed with a controlled size and PDI values by applying the models
obtained from experimental design: (A,C) PC liposomes and (B,D) S60:Cho niosomes (1:0.5, w/w).
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638 The most important variables identiﬁed by ANOVA were the
639 organic/aqueous phase volume ratio, the (ﬁnal aqueous-phase)
640 phospholipid concentration, and the sonication amplitude.
641 These results oﬀer new insights into themechanism and eﬀects
642 of the factors involved in nanovesicle preparation by the EIM,
643 one of the most easily scaled-up methods for preparing vesicles
644 for several ﬁelds of interest.
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(3)678 Pando, D.; Gutieŕrez, G.; Coca, J.; Pazos, C. Preparation and
679 characterization of niosomes containing resveratrol. J. Food Eng. 2013,
680 117, 227−234.
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